FiercePharma

KOMBIGLYZE™ XR (Saxagliptin and Metformin HCl Extended-Release) Tablets Approved in the U.S. for the Treatment of Type 2 D

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE ™ ...
WRIC

Extended-release morphine tablets recalled

WASHINGTON, D.C. (WRIC) — Virginians who take morphine to manage pain are asked to check their bottles after a voluntary recall. Bryant Ranch Prepack, Inc. is voluntarily recalling one lot of 30mg ...
FiercePharma

FDA Approves Mallinckrodt’s EXALGO® (hydromorphone HCl) Extended-Release Tablets 32 mg (CII) for Opioid-Tolerant Patients with Moderate-to-Severe Chronic Pain

<0> CovidienLynn Phillips, 314-654-3263Manager, Media RelationsPharmaceuticalsorColeman Lannum, CFA, 508-452-4343Vice PresidentInvestor RelationsorStephen Littlejohn ...
Nasdaq

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Monthly Prescribing Reference

FDA accepts NDA for extended release Aricept, a treatment for Alzheimer’s disease (AD)

Eisai and Pfizer announced that the FDA has accepted for review the New Drug Application (NDA) for once-daily 23 mg Aricept (donepezil HCl extended release tablets) for the treatment of moderate to ...
Yahoo Finance

Kye Pharmaceuticals Announces the Approval of DYANAVEL® XR (amphetamine extended-release) Tablets and Oral Suspension for the Treatment of Adults and Children With ADHD

MISSISSAUGA, ON, Aug. 5, 2025 /CNW/ - Kye Pharmaceuticals Inc. ("Kye"), a leading Canadian-based commercial-stage specialty pharmaceutical company focused on licensing and commercializing innovative ...
Kalkine Media

Soleno Therapeutics (NASDAQ:SLNO) Nasdaq Index Clinical Pipeline Growth

Soleno Therapeutics (NASDAQ:SLNO) drives innovation in rare disease treatments, often discussed within the Nasdaq index.
Healio

FDA approves Xeljanz extended release tablets for ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . “Ulcerative colitis is a chronic inflammatory disease of the colon that can significantly affect a patient’s ...
Business Wire

Zydus launches Mirabegron Extended-Release Tablets in the US

AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) announces the launch of ...
USA Today

Nostrum Laboratories, Inc. Expands Voluntary Nationwide Recall of Metformin HCl Extended Release Tablets, USP 750 mg, Due to N-Nitrosodimethylamine (NDMA) Content Above the ...

Nostrum Laboratories, Inc. is voluntarily recalling one lot of Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) to the consumer level. The Metformin HCl ...
FierceBiotech

FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for ADHD Treatment

FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents First once-daily nonstimulant to be ...